The authors regret that Table 3 in the originally published article was incomplete in that the intended color coding did not appear, and would like to publish this corrigendum to correct the error. Please refer to the attached Table with full information regarding the guideline recommendations regarding tuberculosis screening in patients receiving biologic immunomodulating medications.
The authors would like to apologise for any inconvenience caused.
Table 3. Summary of biologic medications with indications, TB risk, guideline recommendations and our data.
| Medication Category | Name | IMID indications per FDA labels | Incidence* | TB risk** | WHO, ERS, ACG | ATS/IDSA/CDC, USPSTF | ESCMID | ACR, EULAR | AAD/NPF | FDA label | Evidence Level** | Our data (% tested) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TNFα inhibitors | Adalimumab | RA, JIA, PsO/PsA, SpA, Crohn's | 90-215 | Increased | Recommend | Consider | Recommend | Recommend | Recommend | Recommend | Strong | 83.6 |
| Certolizumab pegol | RA, Crohn's | 474.29 | Increased | Recommend | Consider | Recommend | Recommend | Recommend | Recommend | Strong | ||
| Etanercept | RA, JIA, PsO/PsA, SpA | 9.3-80 | Increased | Recommend | Consider | Recommend | Recommend | Recommend | Recommend | Strong | ||
| Golimumab | RA, PsA, SpA | 172.13 | Increased | Recommend | Consider | Recommend | Recommend | Recommend | Recommend | Strong | ||
| Infliximab | Crohn's, UC, RA, SpA, psoriasis/PsA | 52.5-2558 | Increased | Recommend | Consider | Recommend | Recommend | Recommend | Recommend | Strong | ||
| Selective Co-stimulation Modulators | Abatacept | RA, JIA | 0-230 | Likely not increased | N/A | Consider | N/A | Recommend | N/A | Recommend | Weak | 77.0 |
| Anti-CD20 monoclonal antibody | Rituximab | RA, GPA / MPA | 0-32 | Likely not increased | N/A | Consider | N/A | Recommend | N/A | N/A | Weak | 39.2 |
| IL-1 inhibitor | Anakinra | RA | N/A | Insufficient data | N/A | Consider | Consider | N/A | N/A | N/A | Weak | 55.6 |
| IL-6 inhibitors | Tocilizumab | RA, GCA, JIA | 0-230 | Likely not increased | N/A | Consider | Recommend | Recommend | N/A | Recommend | Weak | 82.8 |
| Sarilumab | RA | 0 | Insufficient data | N/A | Consider | Recommend | Recommend | N/A | Recommend | Weak | ||
| JAK inhibitors | Tofacitinib | RA, PsA, UC | 200-210 | Likely increased | N/A | Consider | Consider | Recommend | N/A | Recommend | Weak | 69.1 |
| Baricitinib | RA | 150-230 | Likely increased | N/A | Consider | Consider | Recommend | N/A | Recommend | Weak | ||
| Upadacitinib | RA, PsA | N/A | Insufficient data | N/A | Consider | Consider | Recommend | N/A | Recommend | Weak | ||
| IL-12/IL-23 inhibitors | Ustekinumab | Psoriasis/PsA, Crohn's | 0-22.12 | Not increased | N/A | Consider | Consider | N/A | Recommend | Recommend | Weak | 87.0 |
| IL-17 inhibitors | Secukinumab | PsO/PsA, SpA | 0-5 | Not increased | N/A | Consider | Consider | N/A | Recommend | Recommend | Weak | 89.3 |
| Ixekizumab | PsO/PsA, SpA | 0 | Likely not increased | N/A | Consider | Consider | N/A | Recommend | Recommend | Weak | ||
| Brodalumab | PsO | N/A | Insufficient data | N/A | Consider | Consider | N/A | Recommend | Recommend | Weak | ||
| IL-23 inhibitors | Guselkumab | PsO | N/A | Likely not increased | N/A | Consider | N/A | N/A | Recommend | Recommend | Weak | 86.3 |
| Tildrakizumab | PsO | N/A | Likely not increased | N/A | Consider | N/A | N/A | Recommend | Recommend | Weak | ||
| Risankizumab | PsO/PsA, Crohn's | N/A | Likely not increased | N/A | Consider | N/A | N/A | Recommend | Recommend | Weak | ||
| Integrin inhibitor | Vedolizumab | UC, Crohn's | 7-100 | Likely not increased | N/A | Consider | N/A | N/A | N/A | Consider | Weak | 85.7 |
*Per 100,000 patient-years. **Author consensus.
“Recommend“: Guideline recommends TB screening tests. ”Consider“: Guideline recommends considering testing if clinical and/or epidemiologic risk factor is present. ”N/A“: No specific recommendations.
TNF: tumor necrosis factor; CD: cluster of differentiation; IL: interleukin; IMID: immune mediated inflammatory disease; FDA: Food and Drug Administration; RA: rheumatoid arthritis; JIA: juvenile idiopathic arthritis; PsO: plaque psoriasis; PsA: psoriatic arthritis; SpA: axial spondyloarthropathy; UC: ulcerative colitis; GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; TB: tuberculosis; WHO: World Health Organization; ERS: European Respiratory Society; ACG: American College of Gastroenterology; ATS: American Thoracic Society; IDSA: Infectious Disease Society of America; CDC: Center for Disease Control and Prevention; USPSTF: United States Preventive Services Task Force; ESCMID: European Society of Clinical Microbiology and Infectious Disease: ACR: American College of Rheumatology; EULAR: European Alliance of Associations for Rheumatology; AAD: American Academy of Dermatology; NPF: National Psoriasis Foundation.